Rapa Therapeutics

AAVogen Inc, based in Rockville, MD, is a pioneering biotechnology company specializing in gene therapy for muscle wasting diseases. With a focus on inclusion body myositis, Duchenne muscular dystrophy, and cancer cachexia, AAVogen's AVGN7 gene therapy has shown promising results in pre-clinical studies, effectively stabilizing muscle structure, increasing muscle mass and strength, and preventing muscle wasting. Driven by a personal mission, AAVogen was founded by a family directly affected by three muscle wasting diseases, fueling their unwavering commitment to developing safer and more effective therapies. AVGN7 has demonstrated its efficacy in various animal models, restoring muscle mass and strength even after wasting has occurred, and it can be administered directly into muscles or systemically. AAVogen also emphasizes patient outreach and education, providing support and information to individuals battling muscle wasting diseases.Generated from the website

VLP Therapeutics is a biotech company based in Gaithersburg, MD, specializing in the development of innovative vaccine technologies. Their i-VLP vaccine technology aims to revolutionize the treatment of diseases that currently lack effective treatment, with the potential to make significant contributions to global public health. With a focus on surface antigen display, interior gene delivery, native virus modification, and replicon platforms, VLP Therapeutics is dedicated to creating breakthrough treatments for cancer, infectious diseases, and influenza. They have recently initiated a Phase 3 clinical trial for a self-amplifying replicon RNA COVID-19 booster targeting the Omicron variant, and have secured funding to develop vaccines while establishing an investigational vaccine manufacturing facility.Generated from the website

Orgenesis Inc, based in Germantown, MD, is a pioneering company dedicated to unlocking the full potential of cell and gene therapies (CGTs) in an affordable and accessible format. Their innovative POCare Platform offers a pathway to lower costs and standardized CGTs, aiming to bring advanced therapies to patients globally. With a focus on personalized CGTs, Orgenesis is committed to addressing the world's most challenging diseases. Through collaborations with biotech industry leaders, research institutes, and hospitals, they are revolutionizing drug development and scale-up, making advanced therapies more accessible to those in need.Generated from the website